{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-071211","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2026-06-08T13:01:47+00:00","discovered_at":"2026-06-08T13:03:00.249482+00:00","generated_at":"2026-06-08T13:03:32.633608+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MetaVia DA-1726 48mg cohort achieves 9.1% weight loss at Day 54; vanoglipel combo shows synergy in MASH/T2D","bullets":["DA-1726 Phase 1 48mg cohort: 9.1% mean weight loss at Day 54 (p<0.05 vs placebo), no plateau observed.","Waist circumference reduced by 9.8 cm at Day 54; BMI reduced by 3.4 kg/m².","Vanoglipel + resmetirom in MASH mouse model: 23.6% weight loss vs control, ALT reduction 83.5%.","Vanoglipel + metformin in T2D model: 16.3% weight loss, 28.7% non-fasting glucose reduction.","Phase 1 Part 3 titration studies for higher-dose DA-1726 ongoing; results expected Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-071211","json":"https://secwatch.observer/filing/0001104659-26-071211.json","markdown":"https://secwatch.observer/filing/0001104659-26-071211.md","text":"https://secwatch.observer/filing/0001104659-26-071211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926071211/0001104659-26-071211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926071211/mtva-20260608x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:03:32.633608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}